STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL

Slides:



Advertisements
Similar presentations
The TB Alliance-Bayer Moxifloxacin Deal
Advertisements

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
TB/HIV Research Priorities: TB Preventive Therapy.
New approaches in TB diagnosis and treatment Prof. M.A. Tageldin.
A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
Southern Africa out of control Swaziland South Africa Namibia Botswana Zimbabwe Lesotho Zambia
Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.
Anri Uys (MSc Pharmacology, BPharm NWU) Medicines Information Centre, Division of Clinical Pharmacology University of Cape Town.
Ongoing trials with new drugs/regimens: the fluoroquinolone case J. Grosset, E. Nuermberger & R.Chaisson Center for TB Research, Johns Hopkins University.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
An agency of the European Union Presented by: Paolo Tomasi Data Safety Monitoring Boards / Data Monitoring Committees in paediatric studies Paolo Tomasi,
Revising the WHO TB Treatment Guidelines Process and new recommendations Malgosia Grzemska Matteo Zignol Stop TB Department World Health Organization DEWG.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
1 EFFICACY OF SHORT COURSE AMOXICILLIN FOR NON-SEVERE PNEUMONIA IN CHILDREN (Hazir T*, Latif E*, Qazi S** AND MASCOT Study Group) *Children’s Hospital,
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
STREAM & TRUNCATE trials Andrew Nunn MRC Clinical Trials Unit at UCL Institute of Clinical Trials and Methodology University College, London, UK.
Christo van Niekerk, M.D. IUATLD Meeting, Cape Town December 5, 2015 TB Alliance Ongoing Clinical Trials in DS-, MDR-and XDR-TB.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Roundtable. Detection and treatment of TB Andrew Black.
Novel Regimen Options for DR-TB Treatment
Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis UZ-UCSF ARD April 08, 2016 W.Samaneka MBChB, MSc Clin Epi, Dip HIV Man.
Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (ST REAM) Nehemiah Nhando UZ-UCSF ANNUAL RESEARCH DAY.
World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Treatment for Multi-drug Resistant TB
The story of Munya* (and us)
A Way out of Directly Observed Therapy (DOT): Community approaches to Self-Administered Treatment for Rifampicin Resistant Tuberculosis in Khayelitsha,
How To Design a Clinical Trial
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Charles D. Wells, MD Chief, International Research and Programs Branch
World Tuberculosis Day 2014
On behalf of The MTN-020/ASPIRE Study Team
Community Participation in Research
Alcohol, Other Drugs, and Health: Current Evidence
2. Active TB drug-safety monitoring : rationale and mechanisms in the context of TB & MDR-TB treatment Multi-partner training package on active TB drug.
Getting to the second 90 in adolescent HIV: What is needed
MDR-TB Update Dr Kelvin Charambira
Safe and effective bedaquiline treatment of drug-resistant tuberculosis (DR-TB) within the National Bedaquiline Clinical Access Programme in South Africa.
Community Advisory Boards on Repeat:
اپيدميولوژي و كنترل سِل
World Health Organization
The results are in: now what?
Chair, DR-TB STAT Task Force
Global programmatic use of bedaquiline and delamanid for drug-resistant TB treatment: progress, challenges, and possible solutions Dr. Vivian Cox Chair,
STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Session 4: Expanded indications for bedaquiline and delamanid
Impact of Using Fixed Dose Combinations (FDCs) versus
Impact of Using Fixed Dose Combinations (FDCs) versus
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
Goal Objectives Expected Outcomes
Anthony D Harries Ministry of Health, Malawi
Improving the Use of Medications to Treat Complex Health Problems in Resource-Poor Settings: Community-Based Examples from Haiti and Peru Jennifer Furin,
MDR-TB Clinical Trials Landscape Overview: Current and Future Trials
Surveillance, Monitoring and Evaluation Working Group
TRANSITION TO TLD – ZIMBABWE REPORT
Treatment of Drug Resistant TB - Questions
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
Preventing recurrent TB in high HIV-prevalent areas
Aparna Raychaudhuri, Ph. D
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
Presentation transcript:

STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL 26th October 2016

Why is a randomised controlled trial needed? To eliminate the risk that patient selection biased results obtained from cohort studies To assess the 9-month regimen in a variety of settings including high levels of HIV-coinfection To develop a better evidence base for MDR-TB treatment If successful, to provide a new standard of care for comparison with potentially better regimens

A parallel approach to assessing the effectiveness of the Bangladesh regimen Cohort studies Randomised trials African countries including: Cameroon Benin Niger Swaziland Afghanistan Uzbekistan STREAM Stage 1 STREAM Stage 2

STREAM Stage 1 study design STREAM Stage 1 is a randomised controlled trial of non-inferiority design currently being conducted in Ethiopia, South Africa, Vietnam and Mongolia The control regimen (A) is the locally used WHO 2011 recommended regimen The study regimen (B) is closely similar to the regimen used in Bangladesh with the exception that high dose moxifloxacin replaces high dose gatifloxacin

The 9-month regimen (B) Weeks Drug doses by weight group Drug < 33 kg 33 - 50 kg > 50 kg Kanamycin* 1 - 16 15 mg per kilogramme body weight Isoniazid (H) 1 - 16 300 mg 400 mg 600 mg Prothionamide 1 - 16 250 mg 500 mg 750 mg Clofazimine 1 - 40 50 mg 100 mg 100 mg Moxifloxacin 1 - 40 400 mg 600 mg 800 mg Ethambutol 1 - 40 800 mg 800 mg 1200 mg Pyrazinamide 1 - 40 1000 mg 1500 mg 2000 mg Kanamycin 3 times/week after week 12 The intensive phase may be extended by 4 or 8 weeks if smear conversion has not occurred by 16 or 20 weeks

Stage 1: current status Enrolment to Stage 1 commenced: July 2012 Sites: Ethiopia (2), South Africa (3), Vietnam and Mongolia 424 of initial target of 400 patients enrolled Intake closed: June 30th 2015 Primary endpoint at 30 months Last patient visit: Q4 2017 Results from Stage 1 expected: Q1/2 2018 95% seen at 52 weeks or known to have died

STREAM Stage 2 Following the provisional licensing of bedaquiline we were asked to consider: is it possible to include additional regimens to the STREAM trial in its present form? if so, what would be the appropriate regimen(s) to evaluate? After extensive discussions between the study partners and other experts it was agreed that the primary interest to patients and programmes would be: a fully oral regimen (no kanamycin) and/or a shorter and simpler regimen

Regimens for Stage 2

Stage 2: two new regimens Regimen C fully oral regimen involves the removal of the injectable, kanamycin, to avoid the associated risks of hearing loss and kidney damage Regimen D treatment is shortened to 28 weeks with a shorter intensive phase (reduced duration of kanamycin and isoniazid) and removal of ethambutol (of questionable efficacy) and removal of prothionamide (commonly associated with severe gastric symptoms) In both regimens bedaquiline is given throughout and moxifloxacin is replaced by levofloxacin to reduce the risks of QTc prolongation

STREAM Study Population (Stage 1 and 2) Adults (18 years or older) who has given consent for treatment and follow-up – adolescents aged 15 or older eligible in Stage 2 Smear-positive pulmonary tuberculosis, unless HIV-infected Evidence of initial resistance to rifampicin on line-probe assay, GeneXpert or other DST No evidence of initial resistance to fluoroquinolone or 2nd-line injectables on line-probe assay No pre-existent QT prolongation >500msec (450 ms in Stage 2)

STREAM Stage 2 design Because it is possible that the control regimen, Regimen B, might not be found to be non-inferior to Regimen A it was decided to continue to enrol patients to Regimen A Secondary objectives include the comparisons of Regimen C and Regimen D to Regimen A; these will be particularly important if Regimen B is found to be inferior to Regimen A

STREAM Stage 2 Design Primary objectives: To assess whether Regimen C (fully oral), and/or Regimen D (6-months), are as effective as, or are superior to, Regimen B (modified Bangladesh regimen) at 76 weeks (18 months) Randomisation ratio: 1:2:2:2 (A:B:C:D) Sample size: 1155 Long term follow-up to 132 weeks (~2.5 years) Funding from USAID & Janssen Intention to submit results to FDA for full licensing application

WHO issued new guidelines May 2016 WHO issued new guidelines Which is the shorter MDR-TB regimen that WHO-recommends? The regimen recommended by WHO is the one which has been used more recently in different geographical sites and in the STREAM trial What is the dosage of medicines to use in the WHO-recommended shorter MDR-TB regimen? The recommended dosage by weight is the one which has been published earlier by the Global Drug-resistant TB Initiative (GDI) in 2015 and the STREAM trial Why is WHO recommending the use of the shorter MDR-TB regimen if the certainty in the evidence is very low? There are considerable benefits to both the patients and to the health systems if the shorter MDR-TB regimen is used instead of longer treatment options. Although the evidence for the effectiveness of the shorter MDR-TB regimen is still considered of very low quality, the outcomes from the observational studies assessed to date do show high levels of success in selected patients treated in different settings.

Implications of WHO recommendations for STREAM In view of WHO’s recommendations it is likely that arm A (the 24 month regimen) will have to be dropped from some sites in Stage 2 of STREAM South Africa is likely to be the first country to adopt the new regimen. In the meantime patients will continue to be randomised to all four arms, A, B, C and D

What if? What if Regimen B is inferior to Regimen A - will there be sufficient patients randomised to Regimen A to compare with C and D? - if not a network meta-analysis will be needed to compare: B with A (Stage 1) C and D with B (Stage 2) In a network meta-analysis three or more treatments are compared using both direct comparisons of interventions within randomised controlled trials and indirect comparisons across trials based on a common comparator.

STREAM Stage 2 April 2016: First patient enrolled (Mongolia) Five sites now open to recruitment (recruitment paused in Ethiopia due to state of emergency) Additional sites planned for Africa, Asia and Eastern Europe

Community Engagement In STREAM Stage 2, Mongolia and South Africa have established regular community engagement activities and CAB meetings Preliminary CE meetings were held in Ethiopia in September 2016 STREAM Community Engagement Plan launched in in Durban in July 2016 (available on TREAT TB website together with video)